Clinical Trials on Non-small Cell Lung Cancer Stage IIIA

Total 8628 results

National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (DoceRamPem)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Non-Small Lung Cell Cancer | Recurrent Non-Small Lung Cell Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed Subtype

United States
University of Colorado, Denver

Recruiting

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Non-Small Cell Lung Cancer | ALK Gene Mutation | EGFR Gene Mutation | BRAF V600E | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | ROSE Cluster 1

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
Stanford University

Completed

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | KRAS Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
Washington University School of Medicine
Polaris Group

Recruiting

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Small Cell Lung Carcinoma | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
OncoHost Ltd.

Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments (PROPHETIC)

Stage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant Melanoma

United States, Israel, United Kingdom, Germany, Spain
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
University of California, San Francisco
Takeda; Array BioPharma

Terminated

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Progressive Disease | Stage IV Lung Cancer | Lung Non-Small Cell Carcinoma | ROS1 Gene Rearrangement | ALK Gene Rearrangement | Stage IIIB Lung Cancer | Stage IIIC Lung Cancer | Stage IVA Lung Cancer | Stage IVB Lung Cancer

United States
Shanghai Chest Hospital

Recruiting

Molecular Analysis and Treatment Options of SCLC

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined Type

China
Vanderbilt-Ingram Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Limited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; NovoCure Ltd.

Terminated

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage... and other conditions

United States
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

Anorexia | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

Non-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung Cancer

Brazil, Canada
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Wake Forest University Health Sciences

Recruiting

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage III | Unresectable Non-Small Cell Lung Carcinoma

United States
University of Maryland, Baltimore
University of Maryland, College Park

Terminated

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies (0805GCC)

Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive Malignancies

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Photodynamic Therapy in Treating Patients With Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
European Organisation for Research and Treatment...

Withdrawn

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (SOLUTION)

Squamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
University Hospital, Angers
University Hospital, Rouen; Central Hospital, Nancy, France; University Hospital... and other collaborators

Unknown

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient (FLT-THERA)

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent | No EGFR Activating Mutation

France
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

KRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

United States, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
University of Washington
AstraZeneca

Withdrawn

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma
Mahmut Gumus

Active, not recruiting

DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS (REGISTURK-LUNG)

Non Small Cell Lung Cancer | Small-cell Lung Cancer

Turkey
Rigshospitalet, Denmark

Completed

Exercise in Advanced Stage Lung Cancer Patients (EXHALE)

Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage

Denmark
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
AstraZeneca

Completed

Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf (Lung-EPICLIN/G)

Non Small Cells Lung Cancer

Qatar, Bahrain, United Arab Emirates

Clinical Trials on Non-small Cell Lung Cancer Stage IIIA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations